Li Chao Zheng, Ogawa Hiromi, Ng Soon Seng, Chen Xindi, Kishimoto Eriko, Sakabe Kokoro, Fukami Aiko, Hu Yueh-Chiang, Mayhew Christopher N, Hellmann Jennifer, Miethke Alexander, Tasnova Nahrin L, Blackford Samuel J I, Tang Zu Ming, Syanda Adam M, Ma Liang, Xiao Fang, Sambrotta Melissa, Tavabie Oliver, Soares Filipa, Baker Oliver, Danovi Davide, Hayashi Hisamitsu, Thompson Richard J, Rashid S Tamir, Asai Akihiro
Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
JHEP Rep. 2022 Feb 1;4(4):100446. doi: 10.1016/j.jhepr.2022.100446. eCollection 2022 Apr.
BACKGROUND & AIMS: The truncating mutations in tight junction protein 2 (TJP2) cause progressive cholestasis, liver failure, and hepatocyte carcinogenesis. Due to the lack of effective model systems, there are no targeted medications for the liver pathology with TJP2 deficiency. We leveraged the technologies of patient-specific induced pluripotent stem cells (iPSC) and CRISPR genome-editing, and we aim to establish a disease model which recapitulates phenotypes of patients with TJP2 deficiency.
We differentiated iPSC to hepatocyte-like cells (iHep) on the Transwell membrane in a polarized monolayer. Immunofluorescent staining of polarity markers was detected by a confocal microscope. The epithelial barrier function and bile acid transport of bile canaliculi were quantified between the two chambers of Transwell. The morphology of bile canaliculi was measured in iHep cultured in the Matrigel sandwich system using a fluorescent probe and live-confocal imaging.
The iHep differentiated from iPSC with mutations exhibited intracellular inclusions of disrupted apical membrane structures, distorted canalicular networks, altered distribution of apical and basolateral markers/transporters. The directional bile acid transport of bile canaliculi was compromised in the mutant hepatocytes, resembling the disease phenotypes observed in the liver of patients.
Our iPSC-derived in vitro hepatocyte system revealed canalicular membrane disruption in TJP2 deficient hepatocytes and demonstrated the ability to model cholestatic disease with TJP2 deficiency to serve as a platform for further pathophysiologic study and drug discovery.
We investigated a genetic liver disease, progressive familial intrahepatic cholestasis (PFIC), which causes severe liver disease in newborns and infants due to a lack of gene called TJP2. By using cutting-edge stem cell technology and genome editing methods, we established a novel disease modeling system in cell culture experiments. Our experiments demonstrated that the lack of TJP2 induced abnormal cell polarity and disrupted bile acid transport. These findings will lead to the subsequent investigation to further understand disease mechanisms and develop an effective treatment.
紧密连接蛋白2(TJP2)的截短突变会导致进行性胆汁淤积、肝衰竭和肝细胞癌变。由于缺乏有效的模型系统,目前尚无针对TJP2缺乏所致肝脏病变的靶向药物。我们利用患者特异性诱导多能干细胞(iPSC)技术和CRISPR基因组编辑技术,旨在建立一个能够重现TJP2缺乏患者表型的疾病模型。
我们在Transwell膜上以极化单层的形式将iPSC分化为肝样细胞(iHep)。通过共聚焦显微镜检测极性标记物的免疫荧光染色。在Transwell的两个腔室之间对胆小管的上皮屏障功能和胆汁酸转运进行定量分析。使用荧光探针和实时共聚焦成像技术,在基质胶三明治系统中培养的iHep中测量胆小管的形态。
由带有突变的iPSC分化而来的iHep表现出细胞内顶端膜结构破坏的包涵体、扭曲的胆小管网络、顶端和基底外侧标记物/转运体分布改变。突变肝细胞中胆小管的定向胆汁酸转运受损,类似于在患者肝脏中观察到的疾病表型。
我们的iPSC来源的体外肝细胞系统揭示了TJP2缺乏的肝细胞中胆小管膜的破坏,并证明了能够模拟TJP2缺乏所致胆汁淤积性疾病,作为进一步病理生理学研究和药物发现的平台。
我们研究了一种遗传性肝病——进行性家族性肝内胆汁淤积症(PFIC),由于缺乏一种名为TJP2的基因,该病会在新生儿和婴儿中引发严重肝病。通过使用前沿的干细胞技术和基因组编辑方法,我们在细胞培养实验中建立了一种新型疾病建模系统。我们的实验表明,TJP2的缺乏会导致细胞极性异常和胆汁酸转运受损。这些发现将引发后续研究,以进一步了解疾病机制并开发有效的治疗方法。